See more : Southwestern Energy Company (SWN) Income Statement Analysis – Financial Results
Complete financial analysis of Myovant Sciences Ltd. (MYOV) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Myovant Sciences Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
- NEO Battery Materials Ltd. (NBMFF) Income Statement Analysis – Financial Results
- National Building and Marketing Co. (9510.SR) Income Statement Analysis – Financial Results
- Coach A Co., Ltd. (9339.T) Income Statement Analysis – Financial Results
- Baker Hughes Company (68V.DE) Income Statement Analysis – Financial Results
- Pioneer Merger Corp. (PACXW) Income Statement Analysis – Financial Results
Myovant Sciences Ltd. (MYOV)
About Myovant Sciences Ltd.
Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It is also developing MVT-602, an oligopeptide kisspeptin agonist, which is in Phase II clinical trial for the treatment of female infertility as part of assisted reproduction. Myovant Sciences Ltd. has collaboration with Pfizer Inc. to develop and commercialize relugolix in oncology and women's health. The company was formerly known as Roivant Endocrinology Ltd. and changed its name to Myovant Sciences Ltd. in May 2016. The company was incorporated in 2016 and is based in London, the United Kingdom. Myovant Sciences Ltd. is a subsidiary of Sumitovant Biopharma Ltd.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|
| Revenue | 230.97M | 59.32M | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 51.55M | 1.97M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 179.42M | 57.35M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 77.68% | 96.69% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 107.40M | 136.71M | 192.56M | 222.61M | 116.83M | 43.50M |
| General & Administrative | 0.00 | 0.00 | 82.33M | 42.22M | 24.23M | 12.36M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 259.36M | 181.42M | 82.33M | 42.22M | 24.23M | 12.36M |
| Other Expenses | 40.04M | 1.66M | 1.62M | -309.00K | 67.00K | -139.00K |
| Operating Expenses | 366.77M | 318.14M | 274.89M | 264.83M | 141.06M | 55.86M |
| Cost & Expenses | 418.32M | 320.10M | 274.89M | 264.83M | 141.06M | 55.86M |
| Interest Income | 384.00K | 211.00K | 2.55M | 881.00K | 0.00 | 0.00 |
| Interest Expense | 13.97M | 10.40M | 12.66M | 8.82M | 2.05M | 0.00 |
| Depreciation & Amortization | 3.46M | 2.69M | 1.77M | 438.00K | 243.00K | 61.00K |
| EBITDA | -183.89M | -258.09M | -273.80M | -255.88M | -140.75M | 0.00 |
| EBITDA Ratio | -79.62% | -435.11% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -187.35M | -260.78M | -270.71M | -264.83M | -141.06M | -55.86M |
| Operating Income Ratio | -81.11% | -439.64% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -13.59M | 5.99M | -17.51M | -8.25M | -1.98M | -27.66M |
| Income Before Tax | -200.93M | -254.80M | -288.23M | -273.08M | -143.04M | -83.51M |
| Income Before Tax Ratio | -86.99% | -429.55% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 5.05M | 336.00K | 761.00K | 476.00K | 213.00K | -74.00K |
| Net Income | -205.98M | -255.13M | -288.99M | -273.55M | -143.26M | -83.44M |
| Net Income Ratio | -89.18% | -430.12% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -2.22 | -2.83 | -3.37 | -4.09 | -2.41 | -1.70 |
| EPS Diluted | -2.22 | -2.83 | -3.37 | -4.09 | -2.41 | -1.70 |
| Weighted Avg Shares Out | 92.97M | 90.04M | 85.84M | 66.91M | 59.52M | 49.18M |
| Weighted Avg Shares Out (Dil) | 92.97M | 90.04M | 85.84M | 66.91M | 59.52M | 49.18M |
Myovant Sciences to Participate in the Goldman Sachs 43rd Annual Global Healthcare Conference
Myovant Sciences Ltd. (MYOV) CEO Dave Marek on Q4 2021 Results - Earnings Call Transcript
Myovant Sciences (MYOV) Reports Q4 Loss, Misses Revenue Estimates
Will Myovant Sciences (MYOV) Report Negative Earnings Next Week? What You Should Know
Here's Why This Analyst Is On Sidelines Despite European Approval Of Myovant's Relugolix For Prostate Cancer
Myovant: Poised To Overcome Regulatory Issues
Myovant Sciences to Host Fourth Fiscal Quarter and Fiscal Year 2021 Earnings Conference Call at 8:30 a.m. Eastern Time on May 10, 2022
Myovant Sciences provides an update on a supplemental new drug
Regulatory Setback Brings Myovant Sciences Stock To Attractive Levels
FDA Finds Deficiencies in Myovant (MYOV), Pfizer's Myfembree sNDA
Source: https://incomestatements.info
Category: Stock Reports